Benzinga | Sep 4, 2020 10:35AM EDT

Aegis Capital Maintains Buy on Biomerica, Raises Price Target to $13

Aegis Capital maintains Biomerica (NASDAQ:BMRA) with a Buy and raises the price target from $10 to $13.